{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:10:20Z","timestamp":1793110220122,"version":"4.5.0"},"reference-count":28,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"unspecified","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["W81XWH-16-1-0385"],"award-info":[{"award-number":["W81XWH-16-1-0385"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["W81XWH-19-1-0675"],"award-info":[{"award-number":["W81XWH-19-1-0675"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pennies in Action Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Miles for Moffitt Milestone Award, Moffitt Cancer Center","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"https:\/\/ror.org\/01xf75524","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,12,23]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Patients with metastatic breast cancer (MBC) have limited opportunities for a cure, as they develop resistance to therapies and continually form new metastases. Clinical overt metastases emerge from metastasis-initiating cancer cells (MICs) that disseminate during breast cancer (BC) progression. Currently, there are no available therapies that inhibit MIC dissemination to prevent overt metastasis. We provide preclinical evidence that intratumoral (IT) delivery of type I polarized dendritic cells (DC1) limited the MIC dissemination mechanisms in tumor lesions of human epidermal growth factor receptor 2 (HER2)+ mammary carcinoma. Interferon gamma, a prominent cytokine secreted by T helper 1 and innate-like immune effector cells, inhibited dissemination of MICs from the tumor lesions via the modulation of HER2\/progesterone receptor\/Wnt family member 4\/receptor activator of nuclear factor kappa beta ligand signaling. Importantly, we provide clinical evidence that in patients with stage I\u2013III HER2+ BC, there was significant regression of the primary tumor treated with IT DC1, as well as inhibition of disseminating MIC phenotypes. We observed a reduced burden of MICs in the bone marrow (BM) of patients with stage I\u2013III HER2+BC treated with IT DC1, compared with untreated patients and those treated with standard neoadjuvant HER2 therapies paclitaxel, with or without carboplatin, trastuzumab and pertuzumab (Taxol, Carboplatin, Herceptin and Perjeta or THP). We also treated a single patient with de novo stage IV HER2+ MBC with trastuzumab, pertuzumab and tamoxifen in combination with IT DC1. Remarkably, this treatment resulted in near-complete regression of primary tumor and metastatic disease, along with inhibition of MIC seeding in the BM. These findings suggest an intriguing strategy to inhibit the dissemination of MICs and prevent further overt metastasis in all patients with BC.<\/jats:p>","DOI":"10.1136\/jitc-2025-013590","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T15:35:21Z","timestamp":1767713721000},"page":"e013590","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Intratumoral dendritic cell immunotherapy controls dissemination of metastasis-initiating cancer cells, even in patients with metastatic breast cancer"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct05325632","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05325632","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05325632","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05325632","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05325632","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05325632","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05325632","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1506-5934","authenticated-orcid":false,"given":"Aixa","family":"Soyano","sequence":"first","affiliation":[{"name":"Department of Breast Oncology, Moffitt Cancer Center, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Catherine","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Moffitt Cancer Center, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo S","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Moffitt Cancer Center, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Aldrich","sequence":"additional","affiliation":[{"name":"Clinical Science Division, Moffitt Cancer Center, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem","family":"Soliman","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Moffitt Cancer Center, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sy K","family":"Olson-Mcpeek","sequence":"additional","affiliation":[{"name":"Clinical Science Division, Moffitt Cancer Center, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlyn N","family":"Balsay-Patel","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Moffitt Cancer Center, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige","family":"Aiello","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Moffitt Cancer Center, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly M","family":"Farrell","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Moffitt Cancer Center, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Weinfurtner","sequence":"additional","affiliation":[{"name":"Department of Radiology, Moffitt Cancer Center, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Burgos","sequence":"additional","affiliation":[{"name":"Morsani College of Medicine, University of South Florida, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4519-9570","authenticated-orcid":false,"given":"Brian J","family":"Czerniecki","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Moffitt Cancer Center, Tampa, Florida, USA"},{"name":"Clinical Science Division, Moffitt Cancer Center, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesan","family":"Ramamoorthi","sequence":"additional","affiliation":[{"name":"Clinical Science Division, Moffitt Cancer Center, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"2026010607351515000_14.1.e013590.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03502-3"},{"key":"2026010607351515000_14.1.e013590.2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0010"},{"key":"2026010607351515000_14.1.e013590.3","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15188-x","article-title":"Metastasis-initiating cells induce and exploit a fibroblast niche to fuel malignant colonization of the lungs","volume":"11","author":"Pein","year":"2020","journal-title":"Nat Commun"},{"key":"2026010607351515000_14.1.e013590.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.9327"},{"key":"2026010607351515000_14.1.e013590.5","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-023-01619-2","article-title":"The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy","volume":"25","author":"Wimberger","year":"2023","journal-title":"Breast Cancer Res"},{"key":"2026010607351515000_14.1.e013590.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-020-0628-z"},{"key":"2026010607351515000_14.1.e013590.7","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-018-0083-5","article-title":"Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer","volume":"4","author":"Magbanua","year":"2018","journal-title":"NPJ Breast Cancer"},{"key":"2026010607351515000_14.1.e013590.8","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan0026","article-title":"Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism","volume":"9","author":"Karagiannis","year":"2017","journal-title":"Sci Transl Med"},{"key":"2026010607351515000_14.1.e013590.9","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-018-0256-3"},{"key":"2026010607351515000_14.1.e013590.10","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature20785","article-title":"Early dissemination seeds metastasis in breast cancer","volume":"540","author":"Hosseini","year":"2016","journal-title":"Nature New Biol"},{"key":"2026010607351515000_14.1.e013590.11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30687-4"},{"key":"2026010607351515000_14.1.e013590.12","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-28076-3","article-title":"Primary tumor associated macrophages activate programs of invasion and dormancy in disseminating tumor cells","volume":"13","author":"Borriello","year":"2022","journal-title":"Nat Commun"},{"key":"2026010607351515000_14.1.e013590.13","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1157"},{"key":"2026010607351515000_14.1.e013590.14","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41586-020-2611-3","article-title":"cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity","volume":"584","author":"Ferris","year":"2020","journal-title":"Nature New Biol"},{"key":"2026010607351515000_14.1.e013590.15","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-24-0630"},{"key":"2026010607351515000_14.1.e013590.16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004841","article-title":"Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma","volume":"10","author":"Ramamoorthi","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026010607351515000_14.1.e013590.17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1001\/jamaoncol.2024.5371","article-title":"Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer: A Nonrandomized Clinical Trial","volume":"11","author":"Han","year":"2025","journal-title":"JAMA Oncol"},{"key":"2026010607351515000_14.1.e013590.18","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-025-00742-x","article-title":"A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer","volume":"11","author":"Soliman","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"2026010607351515000_14.1.e013590.19","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000316","article-title":"Phase II study of \u03b1-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer","volume":"8","author":"Toyoda","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026010607351515000_14.1.e013590.20","doi-asserted-by":"crossref","first-page":"110099","DOI":"10.1016\/j.celrep.2021.110099","article-title":"Parity-induced changes to mammary epithelial cells control NKT cell expansion and mammary oncogenesis","volume":"37","author":"Hanasoge Somasundara","year":"2021","journal-title":"Cell Rep"},{"key":"2026010607351515000_14.1.e013590.21","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1038\/s41388-025-03491-0","article-title":"Salvage therapy with allogeneic invariant natural killer cells in a heavily pre-treated germ cell tumor","volume":"44","author":"Garmezy","year":"2025","journal-title":"Oncogene"},{"key":"2026010607351515000_14.1.e013590.22","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0513"},{"key":"2026010607351515000_14.1.e013590.23","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.ymthe.2020.12.037","article-title":"Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway","volume":"29","author":"Jia","year":"2021","journal-title":"Mol Ther"},{"key":"2026010607351515000_14.1.e013590.24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30812-X"},{"key":"2026010607351515000_14.1.e013590.25","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-020-1252-7","article-title":"HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates","volume":"22","author":"Oca\u00f1a","year":"2020","journal-title":"Breast Cancer Res"},{"key":"2026010607351515000_14.1.e013590.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.12.007"},{"key":"2026010607351515000_14.1.e013590.27","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s43018-022-00376-z","article-title":"A local human V\u03b41 T cell population is associated with survival in nonsmall-cell lung cancer","volume":"3","author":"Wu","year":"2022","journal-title":"Nat Cancer"},{"key":"2026010607351515000_14.1.e013590.28","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41392-023-01653-8","article-title":"\u03b3\u03b4 T cells: origin and fate, subsets, diseases and immunotherapy","volume":"8","author":"Hu","year":"2023","journal-title":"Sig Transduct Target Ther"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013590","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T15:35:24Z","timestamp":1767713724000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,6]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/jitc-2025-013590"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013590","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}